M&A - TRINITY BIOTECH PLC

Form Type: F-3

Filing Date: 2025-03-21

Corporate Action: Acquisition

Type: New

Accession Number: 000117891325000965

Filing Summary: Trinity Biotech plc registered a statement on Form F-3 for the resale of up to 4,290,000 American Depositary Shares (ADSs), comprising of 85,800,000 A Ordinary Shares. The ADSs represent Class A Ordinary Shares, and this registration statement is a post-effective amendment to a previously filed F-3 statement from April 2024. Among the ADSs included, 1.79 million were acquired related to the Waveform Acquisition, in which Trinity Biotech acquired the biosensor assets of Waveform Technologies, Inc. The Company highlights that all ADS numbers reflect a recent 1-for-5 reverse ADS split that took effect on February 21, 2024. The agreement allows a selling shareholder, Perceptive Credit Holdings, to offer these shares through various methods, while proceeds from the sale will not benefit Trinity Biotech directly. Risk factors associated with investments in these ADSs include significant indebtedness, challenges in managing acquisitions like the Waveform Acquisition, and risks related to existing operational transformations aimed at maximizing performance and profitability. The registration was filed with the SEC on March 21, 2025, and signifies an ongoing effort by Trinity to manage its capital needs amid a competitive landscape, particularly in the biosensor market.

Document Link: View Document